The selective presence of mortalin chaperone complexes with client proteins such as p53 in cancer compared to healthy cells [77] indicates that the drugs targeted at disruption of mortalin/client protein complexes will not have significant toxicity. This evidence concerns the gene HSPA9 and cancer.